agatolimod sodium

DRUG4 trials

Sponsors

Jonsson Comprehensive Cancer Center, University of Southern California, Mayo Clinic, City of Hope Medical Center

Conditions

Adult Non-Hodgkin LymphomaCiliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueExtraocular Extension MelanomaIris MelanomaLymphomaMetastatic Intraocular Melanoma

Phase 1

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

CompletedNCT00040950

Jonsson Comprehensive Cancer CenterLymphoma

Start: 2002-03-31End: 2007-10-31Updated: 2013-12-19

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

CompletedNCT00438880

Mayo ClinicAdult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma +9

Start: 2004-10-31End: 2014-11-30Updated: 2016-02-04

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

CompletedNCT00722839

City of Hope Medical CenterNonneoplastic Condition

Start: 2006-12-31End: 2012-04-30Updated: 2012-06-25

Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

CompletedNCT00085189

University of Southern CaliforniaCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma +14

Start: 2004-05-31End: 2007-09-30Updated: 2014-05-22

Related Papers

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

2012-03-0770 citations